MWM
REGN icon

Mascoma Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Mascoma Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50
Closed -$17K – 403
2018
Q1 		$17K Hold
50
– – 0.01% 232
2017
Q4 		$17K Hold
50
– – 0.01% 227
2017
Q3 		$22K Hold
50
– – 0.01% 225
2017
Q2 		$25K Hold
50
– – 0.02% 216
2017
Q1 		$19K Hold
50
– – 0.01% 222
2016
Q4 		$18K Buy
+50
New +$19K 0.01% 228

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Mascoma Wealth Management's REGN Position: Q2 2018 in Review

Mascoma Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2018, closing a stake of 50 shares — an estimated $17K sold.

Mascoma Wealth Management first reported a position in REGN in Q4 2016 and held it in 6 quarters. The position peaked at $25K in Q2 2017. 624 funds tracked by Wall St. Rank hold REGN as of Q2 2018.

  • Mascoma Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Mascoma Wealth Management sold 50 Regeneron Pharmaceuticals shares in Q2 2018, an estimated $17K.
  • Mascoma Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2016 and held it in 6 quarters.
  • Mascoma Wealth Management's Regeneron Pharmaceuticals position peaked at $25K in Q2 2017.
  • 624 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2018.

Based on Mascoma Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.